Level D· Scientific groundwork from lab and animal studiesAnimal StudyEurope PMCOpen access

Glycosylated graphene-nylon fiber: A new material platform to balance the nanotoxicity and bioactivity for anti-infective therapy

Li G., Mo J., Jing J., Li L., Ju Y., Ma W.

Animal Study on Chronic Wound, published in Bioact Mater (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Bioact Mater (2026)
Reported sample size
—
Source database
Europe PMC
PMID
41799957
PMCID
PMC12964391
DOI
10.1016/j.bioactmat.2026.02.033

Abstract (original English)

Nanomaterials show great potential for biomedical applications, particularly in addressing challenges such as drug-resistant bacterial infections. However, their clinical use is hindered by considerable obstacles, mainly due to the potential risks associated with nanotoxicity. One effective strategy to mitigate nanotoxicity is the use of nanocomposites, which involve dispersing and immobilizing nanomaterials within polymer matrices. Unfortunately, it often results in a significant reduction in bioactivity. To overcome the challenge of balancing nanotoxicity and bioactivity, novel glycosylated graphene-nylon fibers were designed and synthesized by using an in situ polymerization technique combined with the surface glycan-engineering. By covalently immobilizing graphene nanosheets within the polyamide matrix, the potential health risks associated with graphene migration in vivo were prevented. The glycan coatings on the surface of the graphene-nylon fiber enhanced the antibacterial and antiviral properties through a synergistic effect of pathogen enrichment and oxidative stress. This novel material platform demonstrated outstanding therapeutic efficacy in both healthy mouse wound models and diabetic mouse wound models with drug-resistant bacterial infections, significantly accelerating the wound healing process. Furthermore, the underlying mechanisms were comprehensively explored

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research